An experimental cancer vaccine that utilizes messenger RNA (mRNA) technology has shown promising results in preventing the recurrence of melanoma, marking a potential breakthrough in cancer treatment, researchers say. The vaccine, intismeran autogene, developed by Moderna and Merck, demonstrated success in a Phase 3 clinical trial, according to announcements made earlier this year.

This advance could pave the way for a new class of personalized cancer therapies that customize vaccines to a patient’s specific tumor mutations. The approach involves analyzing a sample of the tumor to identify genetic alterations, then creating a vaccine tailored to target those precise abnormalities. Each patient receives a unique formulation designed to elicit an immune response against their cancer.

Beyond melanoma, ongoing clinical trials are testing mRNA vaccines for other difficult-to-treat cancers, including lung and pancreatic cancers. While some of these treatments remain years or even decades away from potential approval, experts describe the field as rapidly evolving with the capacity to significantly transform cancer care.

Dan Costin, director of the White Plains Hospital Center for Cancer Care in New York and lead investigator of an mRNA lung cancer vaccine trial, explained how the process may become routine in the future. “It is not too far-fetched to consider that in the future, when one is diagnosed with cancer, part of your specimen is going to go to the pathologist, who’s going to confirm the cancer [diagnosis],” Costin said. “And the other part will be going to a laboratory where they will be preparing a special vaccine.”

mRNA technology, which gained widespread attention during the COVID-19 pandemic as the basis for several coronavirus vaccines, works by instructing cells to produce proteins that trigger the immune system. Unlike preventive vaccines, these mRNA cancer vaccines are therapeutic, designed to treat an existing disease by stimulating the body’s immune response to recognize and attack cancer cells.

Researchers remain cautiously optimistic as they continue to evaluate long-term efficacy and safety in larger and more diverse patient populations. Nonetheless, the initial success of intismeran autogene offers a promising glimpse into the future of immunotherapy, where highly individualized treatments might become standard practice in oncology.